COST-UTILITY OF STATIN IN SECONDARY PREVENTION- A PROPENSITY SCORE METHOD OF ADMINISTRATIVE DATABASE
Author(s)
Luque A, Nobre MR, Abrahão MT
Sao Paulo University, Sao Paulo, Brazil
Presentation Documents
OBJECTIVES: Cost-effectiveness analysis for secondary prevention with statins in Brazilian context are few and with efficacy data supported from primary RCT and utility values from foreign populations. Effectiveness from observational database and utility values from a similar population provides real world evidence The aim of this study is to evaluate the cost-utility of secondary prevention with statins in fatal and non-fatal events based on real world data. METHODS: A cohort markov model with five states, annual cycle and time horizon (TH) of 10 years, with discount rate of 5% was developed. A transition probability for total cause mortality was derived from a administrative database of a teaching hospital after record linkage with national registry of mortality database and an analysis of propensity score matchingNon-fatal endpoints were derived after a random effect meta-analysis. Utility measures was calculated with a validated model to derive values from published domains of SF-36 QoL questionnaire. Direct Costs were analyzed from the Brazilian public health perspective. RESULTS: in 0,8% (CI 95% -0,015%;-0,08%)SG with CG, in a 10 year TH, for simvastatin 10mg, 40 mg and atorvastatin 10 mg were, USD1.657.00, USD4.431.00 and R$ CONCLUSIONS: Real world evidence demonstrated that statins are less effective than RCT evidence to reduce all cause mortality in secondary prevention but with very cost-effectiveness strategy according to WHO thresholds.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PCV125
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders